Nektar Therapeutics (NASDAQ:NKTR) Director Lutz Lingnau sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $20.76, for a total value of $622,800.00. Following the transaction, the director now owns 53,450 shares in the company, valued at $1,109,622. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Nektar Therapeutics (NKTR) traded up 4.55% during mid-day trading on Tuesday, hitting $21.60. 2,202,643 shares of the stock traded hands. The stock’s 50 day moving average is $19.50 and its 200-day moving average is $17.40. The company’s market cap is $3.35 billion. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by $0.02. Nektar Therapeutics had a negative return on equity of 3,072.86% and a negative net margin of 150.74%. The firm had revenue of $24.73 million for the quarter, compared to analyst estimates of $29.43 million. During the same quarter last year, the business posted ($0.14) EPS. The firm’s revenue was down 58.0% compared to the same quarter last year. On average, equities research analysts anticipate that Nektar Therapeutics will post ($1.19) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Director Sells 30,000 Shares of Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/18/insider-selling-nektar-therapeutics-nasdaqnktr-director-sells-30000-shares-of-stock.html.

Several analysts have recently commented on NKTR shares. BidaskClub raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a research report on Monday, June 26th. ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Roth Capital set a $31.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Monday, May 22nd. Finally, Jefferies Group LLC reduced their price target on shares of Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $25.25.

Institutional investors have recently bought and sold shares of the company. Prudential Financial Inc. increased its position in Nektar Therapeutics by 1.1% in the first quarter. Prudential Financial Inc. now owns 262,243 shares of the biopharmaceutical company’s stock worth $6,155,000 after buying an additional 2,890 shares in the last quarter. Elkfork Partners LLC increased its position in Nektar Therapeutics by 11.1% in the first quarter. Elkfork Partners LLC now owns 9,520 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 952 shares in the last quarter. Bank of Montreal Can increased its position in Nektar Therapeutics by 21.8% in the first quarter. Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 1,464 shares in the last quarter. State of Tennessee Treasury Department increased its position in Nektar Therapeutics by 20.2% in the first quarter. State of Tennessee Treasury Department now owns 143,644 shares of the biopharmaceutical company’s stock worth $3,371,000 after buying an additional 24,123 shares in the last quarter. Finally, Arizona State Retirement System increased its position in Nektar Therapeutics by 1.9% in the first quarter. Arizona State Retirement System now owns 80,145 shares of the biopharmaceutical company’s stock worth $1,881,000 after buying an additional 1,500 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.